Panel’s Recommendations Antiretroviral therapy (ART) is recommended for all persons with HIV to reduce morbidity and mortality (AI) and to prevent the transmission of HIV to others (AI). The Panel on Antiretroviral Guidelines for Adults and Adolescents recommends initiating ART immediately (or as soon as possible) after HIV diagnosis in order to increase the uptake of ART and …
AU Comment: Treatment goals in Australia The principles of treatment goals of ART in Australia are consistent with DHHS recommendations, noting that in Australia both two and three drug ARV regimens are available. Antiretroviral therapy (ART) has reduced HIV-related morbidity and mortality at all stages of HIV infection1-4 and has reduced HIV transmission.5-8 Maximal and durable suppression …
AU Comment: HLA-B*5701 screening: DHHS recommendations are suitable for implementation in Australia, including: Screening for HLA-B*5701 before starting patients on an abacavir (ABC)-containing regimen to reduce the risk of hypersensitivity reaction (HSR) (AI). Avoidance of ABC- in HLA-B*5701-positive patients and documentation of HLA-B*5701-positive status as an ABC allergy in the patient’s medical record, noting the risk …
AU Comment: Co-receptor Tropism Assays DHHS recommendations are suitable for implementation in Australia, noting that CCR5 tropism testing is only relevant when considering the use of Maraviroc treatment (in which case it is required) or when assessing virological failure involving Maraviroc therapy. In Australia, only genotypic CCR5 tropism assays are available to assess tropism using …
AU Comment: Drug-Resistance testing in Australia DHHS recommendations are suitable for HIV drug resistance testing in Australia, including: Routine baseline HIV-1 genotyping prior to treatment and in the context of virological failure; Incorporation of integrase gene sequencing into routine testing practice; Recommendation around the use of HIV resistance testing in the assessment of virological failure, …
AU Comment: Plasma HIV-1 RNA (Viral Load) and CD4 Count Monitoring Plasma HIV-1 RNA (Viral Load) and CD4 Count Monitoring: Current DHHS guidelines are suitable for implementation in Australia, noting the following principles: Viral load testing Viral load is the most important indicator of initial and sustained response to ART and should be measured in …
Plasma HIV-1 RNA (Viral Load) and CD4 Count Monitoring Read More »
AU Comment: IGRA testing Interferon gamma release assays (IGRAs), such as the QuantiFERON-TB Gold assay, detect circulating T cells reactive with antigens of Mycobacterium tuberculosis (M.tb). The tuberculin skin test (TST) also detects M. tuberculosis-reactive T cells but T cells reactive with antigens of BCG and non-tuberculous mycobacteria may also be detected, resulting in a …
This section has information on laboratory testing. Please click on the below links or follow the table of contents to access the information you are looking for. Tests for Initial Assessment and Follow-Up Drug-Resistance Testing HLA-B* 5701 Screening Plasma HIV-1 RNA (Viral Load) and CD4 Count Monitoring Co-receptor Tropism Assays
AU Comment: Australian resource on primary care guidance for PHIV Australian clinicians can refer to the ASHM HIV Management Guidelines for primary care guidance for people with HIV. AU Comment: Other tests to perform STI testing for people with HIV in Australia should be consistent with the Australian STI Management Guidelines for Use in Primary …
The DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents (a working group of the Office of AIDS Research Advisory Council) has reviewed and updated the text and references of previous versions of the Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. The Sub-Committee for Guidance on HIV Management in Australia …
The ARV Guidelines with Australian commentary is administered by ASHM
The Australian Government Department of Health
Prescribers
Contact Us
Acknowledgement of Country
We pay our respects to the Aboriginal and Torres Strait Islander peoples of the past, present, and future, including the Gadigal peoples (Sydney office), the Turrbal and Jagera/Yuggera peoples (Brisbane office), and all First Nations people of the nations where we live and work.
ASHM Health | ABN 48 264 545 457 | CFN 17788 | Copyright © 2022 ASHM